Awaiting product image

Article: O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

€3.03

SKU: product-article-18262 Category:

Description

O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

Reviews

There are no reviews yet.

Be the first to review “Article: O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma”

Related products